- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01307384
Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup-studie (PMCF)
Prospektiv klinisk uppföljningsstudie efter marknaden av kontinuummetallen på polyetenacetabulärsystemet
This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
California
-
Fremont, California, Förenta staterna, 94538
- Sah Orthopaedic Associates
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80204
- Denver Health Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients from surgeons medical practice who are candidates for primary hip arthroplasty.
The study population will be comprised of 300 males and females who require primary total hip arthroplasty. Subjects will be enrolled at up to 7 clinical sites. Subjects must be geographically accessible throughout the study and be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will be offered informed consent, and eligibility will be determined based upon the inclusion/exclusion criteria.
Beskrivning
Inclusion Criteria
-
Patient is 18 to 75 years of age, inclusive.
-
Patient is skeletally mature.
-
Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:
- Avascular necrosis (AVN)
- Osteoarthritis
- Inflammatory arthritis (i.e., Rheumatoid arthritis)
- Post-traumatic arthritis
-
Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).
-
Patient has moderate, marked or disabling pain.
-
Patient is willing and able to provide written informed consent.
-
Patient is willing and able to cooperate in the required post-operative therapy.
-
Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
-
Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.
Exclusion Criteria:
-
The patient is:
- A prisoner
- Mentally incompetent or unable to understand what participation in the study entails
- A known alcohol or drug abuser
- Anticipated to be non-compliant
-
The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.
-
The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.
-
The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.
-
The patient is known to be pregnant.
-
The patient is unwilling or unable to give consent or to comply with the follow-up program.
-
The patient has received an investigational drug or device within the previous 6 months.
-
The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.
-
The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.
-
The patient has osteoradionecrosis in the affected hip joint.
-
The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.
-
The patient has known local bone tumors and/or cysts in the operative hip.
-
The patient has a Body Mass Index (BMI) > 40.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Continuum Acetabular System
Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System |
Used in primary hip arthroplasty
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Survivorship
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Based on removal or intended removal of the device and determined using the Kaplan-Meier method. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Safety / Adverse Events
Tidsram: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects. |
Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pain and Function / HHS
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Harris Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Pain and Function / OHS
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Oxford Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / SF-12
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Health status will be measured using the SF-12 self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / Radiographic Parameters
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
X-rays will be evaluated for acetabular cup angle, acetabular cup migration, femoral stem position, femoral stem subsidence and femoral stem shift. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Metal Ion / Cobalt
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Chromium
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Titanium
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / BUN
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / Creatinine
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / GFR
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Hillary Overholser, Zimmer Biomet
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Skelettsjukdomar
- Muskuloskeletala sjukdomar
- Patologiska processer
- Ledsjukdomar
- Reumatiska sjukdomar
- Bindvävssjukdomar
- Autoimmuna sjukdomar
- Immunsystemets sjukdomar
- Nekros
- Patologiska tillstånd, tecken och symtom
- Hud- och bindvävssjukdomar
- Artrit
- Artros
- Artrit, reumatoid
- Osteonekros
- Kirurgiska ingrepp, operativ
- Artroplastik, ersättning
- Artroplastik
- Ortopediska förfaranden
- Plastikkirurgiförfaranden
- Protesimplantation
- Artroplastik, ersättning, höft
Andra studie-ID-nummer
- CMU2010-02H
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .